The HC posters have been pretty harsh on management. However the simple fact remains... Biota has an excellent pipeline and the management HAVE been able to strike good partnership arrangements in the past.
Court case was unlucky, poor judgement perhaps. This weeks announcement proves that both stockpiling and seasonal markets could swing Relenza's was. What perfect timing at a time when the stock price is trading around the stock's cash backing!
People are forgetting that Tamiflu had some huge sales figures... I believe one year at around USD2bn. For biota that would be around 200m in royalties!
LANI is coming...
tamiflop now the looser relenza the winner, page-6
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)